Skip to main content

Heart Failure: Evolving Treatment Choices and New Guidance (Regional)

A CME-certified, ABIM MOC-eligible Activity

Click here to complete your registration.

If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.



  • Welcome and Introduction
  • Newer Agents for the Management of HFrEF: Efficacy and Safety
  • Agents in Late-Stage Development for the Management of HF
  • Heart Failure Decision Pathway: 2021 Update
  • Q&A Session and Activity Roundup


The number of Americans with HF is increasing. Despite the many agents approved to manage HF, the prognosis has only improved somewhat, with a 5-year mortality rate after initial hospitalization of 42.3%. Guidelines are frequently updated, with the most recent ACC consensus on optimizing treatment published in 2021. Some agents to treat HFrEF are relatively new and several agents are in late-stage development. For patients with HFpEF there are currently no approved therapies although there are agents in phase 3 clinical trials.

Heart Failure: Evolving Treatment Choices and New Guidance will address the rapidly shifting HF management paradigm, providing information about the most recent evidence-based recommendations for managing HFrEF, newer approved agents, and those agents for which approval is anticipated soon, as well as agents in late-stage investigation for the management of HFpEF.

John J. Ryan, MD, MB, BCH, BAO
Associate Professor
Director, Dyspnea and Pulmonary Hypertension Center
Director, Cardiovascular Medicine Unit
Director, Cardiovascular Medicine Fellowship Program
University of Utah
Salt Lake City, UT

Muthiah Vaduganathan, MD, MPH
Co-Director, Center for Cardiometabolic Implementation Science
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA

The intended audience for this educational initiative is cardiologists, who are clinicians responsible for the management of patients with heart failure.

At the conclusion of this activity, participants should be able to:

  • Evaluate the evidence showing the efficacy and safety of newer agents approved for the management of HFrEF
  • Describe the mechanism of action of and efficacy and safety data for agents in late-stage development for the management of heart failure
  • Develop individualized evidence-based management plans for patients with heart failure that are based on recommendations from the 2021 update to the ACC heart failure decision pathway


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit or the evaluation, please email

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, Heart Failure: Evolving Treatment Choices and New Guidance has met the requirements as a Lifelong Learning CME Activity(apply toward general CME requirement) for the following ABMS Member Boards:

ABMS Lifelong Learning CME Activity
Family Medicine

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of the activity is vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships will be mitigated by PCME.

Disclosure and mitigation information will be made known to the participants prior to the start of the activity.


The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

To ensure your computer is compatible for the live event, please perform a system check by clicking on the link or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.


  • 1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
  • Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
  • 512 MB of RAM (1 GB recommended)
  • Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
  • For HTML Client - Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)


  • 1.83 GHz Intel Core Duo or faster processor
  • 512 MB RAM (1 GB recommended)
  • Mac OS X 10.12, 10.13 and 10.14
  • Mozilla Firefox, Apple Safari, Google Chrome
  • For HTML Client - Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)


  • The Adobe Connect app for iOS and Android requires Adobe Connect Server version 8.2 or later
  • Some features may not be enabled in all Adobe Connect meetings if one is using an Adobe Connect Server older than version 9.4.2 (required for Custom pods)
  • Google Android 4.4 or later
  • Apple iOS: iOS 8.1.2 or later

DSL/cable (wired connection recommended)

There is no fee for this activity. To receive credit, participants must register, view the live CME/MOC activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.

Jointly provided by the Potomac Center for Medical Education and Rockpointe

This program is supported by an educational grant from Merck & Co, Inc.

PCME Privacy Policy